Relapsed/Refractory Follicular Lymphoma

Also known as: Relapsed and Refractory Follicular Lymphoma / Relapsed / Refractory Follicular Lymphoma / Relapsed or Refractory Follicular Lymphoma

DrugDrug NameDrug Description
DB15434MosunetuzumabA humanized anti-CD20/CD3 bispecific antibody used to treat relapsed or refractory follicular lymphoma.
DB15035ZanubrutinibA kinase inhibitor used to treat mantle cell lymphoma, a type of B-cell non-Hodgkin lymphoma, in adults who previously received therapy.
DrugDrug NamePhaseStatusCount
DB00531Cyclophosphamide1Active Not Recruiting1
DB01073Fludarabine1Active Not Recruiting1
DB16272Orelabrutinib2Recruiting1
DB00073Rituximab2Recruiting1
DB13915Axicabtagene ciloleucel3Recruiting1
DB06769Bendamustine3Not Yet Recruiting1
DB06769Bendamustine3Recruiting1
DB00531Cyclophosphamide3Not Yet Recruiting1
DB00531Cyclophosphamide3Recruiting1
DB00997Doxorubicin3Not Yet Recruiting1
DB00997Doxorubicin3Recruiting1
DB01073Fludarabine3Not Yet Recruiting1
DB01073Fludarabine3Recruiting1
DB00480Lenalidomide3Not Yet Recruiting1
DB00480Lenalidomide3Recruiting5
DB16582Lisocabtagene maraleucel3Not Yet Recruiting1
DB15434Mosunetuzumab3Recruiting1
DB08935Obinutuzumab3Recruiting1
DB16684Odronextamab3Recruiting1
DB00635Prednisone3Not Yet Recruiting1
DB00635Prednisone3Recruiting1
DB00073Rituximab3Not Yet Recruiting1
DB00073Rituximab3Recruiting5
DB12887Tazemetostat3Recruiting1
DB00541Vincristine3Not Yet Recruiting1
DB00541Vincristine3Recruiting1
DB15035Zanubrutinib3Recruiting1